GT Biopharma, Inc., a clinical stage immuno-oncology company focused on therapeutics based on the Company’s natural killer (NK) cell engager, TriKE platform, has appointed Gregory Berk, M.D., Chief Medical Officer. Dr. Berk has served as a Director on GT Biopharma’s Board since November 2020, and resigns that post in conjunction with his appointment.
 
Also, Jeffrey S. Miller, M.D., who has supported GT Biopharma as the Company’s Consulting Chief Medical Officer since August 2019, will become Consulting Chief Scientific Officer. Dr. Miller, with his colleagues at the University of Minnesota, is the inventor of the TriKE technology platform. Dr. Miller will continue his leadership role in the design and prosecution of all GT Biopharma TriKE product candidate clinical trials.
 
“We are excited to welcome Dr. Berk as the Company’s Chief Medical Officer as we continue to progress TriKE through the clinic. The addition of Dr. Berk with his extensive clinical trial background, helps advance our current GTB-3550 FDA trial and additional solid tumor TriKE programs currently in manufacturing. Dr. Miller’s move to Consulting Chief Scientific Officer further demonstrates his continued dedication to our advancement of TriKE product candidates in multiple solid tumor and hematologic cancer indications,” said Anthony J. Cataldo, GT Biopharma’s Chairman and Chief Executive Officer. “Dr. Berk’s significant contributions, coupled with his industry and academic expertise, have provided GT Biopharma with invaluable insights for the development of our novel TriKE™ platform and programs, and we look forward to him now taking a more active role.”